These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 19934396

  • 1. Daptomycin versus other antimicrobial agents for the treatment of skin and soft tissue infections: a meta-analysis.
    Bliziotis IA, Plessa E, Peppas G, Falagas ME.
    Ann Pharmacother; 2010 Jan; 44(1):97-106. PubMed ID: 19934396
    [Abstract] [Full Text] [Related]

  • 2. Daptomycin: rationale and role in the management of skin and soft tissue infections.
    Seaton RA.
    J Antimicrob Chemother; 2008 Nov; 62 Suppl 3():iii15-23. PubMed ID: 18829721
    [Abstract] [Full Text] [Related]

  • 3. Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections.
    Logman JF, Stephens J, Heeg B, Haider S, Cappelleri J, Nathwani D, Tice A, van Hout BA.
    Curr Med Res Opin; 2010 Jul; 26(7):1565-78. PubMed ID: 20429820
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials.
    Beibei L, Yun C, Mengli C, Nan B, Xuhong Y, Rui W.
    Int J Antimicrob Agents; 2010 Jan; 35(1):3-12. PubMed ID: 19900794
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin.
    Owens RC, Lamp KC, Friedrich LV, Russo R.
    Am J Med; 2007 Oct; 120(10 Suppl 1):S6-12. PubMed ID: 17904950
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Daptomycin versus vancomycin for complicated skin and skin structure infections: clinical and economic outcomes.
    Davis SL, McKinnon PS, Hall LM, Delgado G, Rose W, Wilson RF, Rybak MJ.
    Pharmacotherapy; 2007 Dec; 27(12):1611-8. PubMed ID: 18041881
    [Abstract] [Full Text] [Related]

  • 13. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience.
    Sakoulas G, Brown J, Lamp KC, Friedrich LV, Lindfield KC.
    Clin Ther; 2009 Sep; 31(9):1936-45. PubMed ID: 19843483
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria.
    Katz DE, Lindfield KC, Steenbergen JN, Benziger DP, Blackerby KJ, Knapp AG, Martone WJ.
    Int J Clin Pract; 2008 Sep; 62(9):1455-64. PubMed ID: 18662172
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.